fool.com
Is it time to buy a basket of biotech stocks?
about 2 years ago
fool.com
Novavax’s milestone means investors can now exhale.
about 2 years ago
fool.com
Author Dr. Frank David breaks down what investors should look for when it comes
to trial design.
about 2 years ago
fool.com
Do some drug trial participants see improvements just because they’re told they
might?
about 2 years ago
fool.com
Pfizer’s foreseeable future looks strong.
about 2 years ago
fool.com
Trial design may matter more than you think.
about 2 years ago
fool.com
What happens after a trial’s results are negative -- or positive?
about 2 years ago
Search by beat, location, outlet & position to find the right journalists for your story.
Sign up for freefool.com
Positive clinical results should be a good thing, right?
about 2 years ago
fool.com
Cutting-edge technology meets traditional healthcare.
about 2 years ago
fool.com
By catering to the needs of medical professionals, Doximity could deliver in a
big way.
about 2 years ago
fool.com
This biotech company is showing early promise.
almost 2 years ago
